**Background of LAMB3 Antibody**
The LAMB3 antibody targets the laminin subunit beta-3 (LAMB3), a key component of laminin-332 (previously laminin-5), an extracellular matrix protein critical for epithelial cell adhesion, migration, and basement membrane assembly. LAMB3. encoded by the *LAMB3* gene, forms heterotrimers with alpha-3 and gamma-2 subunits, creating laminin-332. which anchors epithelial cells to underlying connective tissues via interactions with integrins and other receptors.
Mutations in *LAMB3* are linked to junctional epidermolysis bullosa (JEB), a severe genetic disorder characterized by fragile skin and mucosal blistering. LAMB3 is also implicated in cancer progression, particularly in epithelial-derived tumors (e.g., breast, lung, colon), where its overexpression promotes invasion, metastasis, and resistance to therapy by enhancing cell motility and survival.
LAMB3 antibodies are essential tools in research and diagnostics. They enable detection of LAMB3 expression in tissues or cell lines using techniques like immunohistochemistry (IHC), Western blotting, and immunofluorescence (IF). Clinically, these antibodies aid in diagnosing JEB through genetic testing and assessing laminin-332 deficiencies. In cancer research, they help evaluate LAMB3's role in tumor biology and its potential as a therapeutic target. Commercial LAMB3 antibodies are typically validated for specificity and application compatibility, ensuring reliable results in both basic and translational studies.